![Mark McKenna](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark McKenna
Directeur/Membre du Conseil chez
SPYRE THERAPEUTICS, INC.
Fortune : 824 989 $ au 31/08/2026
Profil
Mr. Mark C.
McKenna is an Independent Director at TCGX Acquisition Corp.
II, a Vice Chairman at NewAmsterdam Pharma Co. NV, a Chairman & Chief Executive Officer at Mirador Therapeutics, Inc., a Managing Director & Chief Investment Officer at Mckenna Capital, LLC and an Independent Director at Helix Acquisition Corp.
III.
He is on the Board of Directors at TCGX Acquisition Corp.
II, NewAmsterdam Pharma Co. NV, Spyre Therapeutics, Inc., Prometheus Laboratories, Inc. and Helix Acquisition Corp.
III.
Mr. McKenna was previously employed as an Independent Director by Perceptive Capital Solutions Corp., an Independent Director by Helix Acquisition Corp.
II, a Chairman by Apogee Therapeutics, Inc., a Chairman, President & Chief Executive Officer by Prometheus Biosciences, Inc., a President by Salix Pharmaceuticals Ltd., and a Senior Vice President & GM-US Vision Care by Bausch & Lomb, Inc. He also served on the board at Rebalance Health, Inc. He received his undergraduate degree from Arizona State University and an MBA from Azusa Pacific University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,03 % | 20/07/2026 | 30 000 ( 0,03 % ) | 443 700 $ | 31/08/2026 |
0,7 % | 23/01/2026 | 30 000 ( 0,7 % ) | 322 500 $ | 31/08/2026 |
| 15/04/2026 | 2 320 ( 0 % ) | 58 789 $ | 31/08/2026 | |
| 27/05/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Postes actifs de Mark McKenna
| Sociétés | Poste | Début |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/02/2024 |
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Directeur/Membre du Conseil | 16/07/2024 |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pharmaceutical and diagnostic products | Directeur/Membre du Conseil | - |
Mckenna Capital, LLC
 Mckenna Capital, LLC Mckenna Capital, LLC is a private equity real estate investment firm specializing in passive real estate syndications, focusing on asset classes such as multifamily apartments, self-storage facilities, manufactured and mobile home parks, and niche sectors like senior living and express car washes. The private company is based in Malvern, PA. The firm acts as co-general partners in joint ventures, enabling accredited and financially sophisticated investors to pool capital with experienced operators. The company emphasizes creating passive income streams and long-term wealth through value-add strategies for income-producing properties. Investors benefit from diversified portfolios, consistent cash flow, equity appreciation, mortgage amortization, and tax advantages, with investment opportunities offered through confidential private offering memoranda. The firm provides educational resources and an investor portal for tracking investments. The company was founded by Stephen T. McGrath. Mark C. Mckenna has been the CEO of the company since 2023. | Directeur Général | 01/06/2023 |
Anciens postes connus de Mark McKenna
| Sociétés | Poste | Fin |
|---|---|---|
| APOE THERPAR | Président | 03/09/2026 |
| PROMETHEUS BIOSCIENCES, INC. | Directeur Général | 16/06/2023 |
| SALIX PHARMACEUTICALS, LTD. | President | 01/08/2019 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Corporate Officer/Principal | 01/01/2016 |
Formation de Mark McKenna
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
61
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Health Technology |
Salix Pharmaceuticals Ltd.
 Salix Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company for the prevention and treatment of gastrointestinal diseases & disorders | Health Technology |
Spyre Therapeutics, Inc.
 Spyre Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biotechnology company | Health Technology |
Arizona State University
 Arizona State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Azusa Pacific University
 Azusa Pacific University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel pharmaceutical and diagnostic products | Health Technology |
Mckenna Capital, LLC
Mckenna Capital, LLC Mckenna Capital, LLC is a private equity real estate investment firm specializing in passive real estate syndications, focusing on asset classes such as multifamily apartments, self-storage facilities, manufactured and mobile home parks, and niche sectors like senior living and express car washes. The private company is based in Malvern, PA. The firm acts as co-general partners in joint ventures, enabling accredited and financially sophisticated investors to pool capital with experienced operators. The company emphasizes creating passive income streams and long-term wealth through value-add strategies for income-producing properties. Investors benefit from diversified portfolios, consistent cash flow, equity appreciation, mortgage amortization, and tax advantages, with investment opportunities offered through confidential private offering memoranda. The firm provides educational resources and an investor portal for tracking investments. The company was founded by Stephen T. McGrath. Mark C. Mckenna has been the CEO of the company since 2023. | |
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops medicines for immune-mediated diseases | Health Technology |
Rebalance Health, Inc.
 Rebalance Health, Inc. Pharmaceuticals: OtherHealth Technology Manufactures supplements for health and stress management & sells through online | Health Technology |
NewAmsterdam Pharma Co. NV
 NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Apogee Therapeutics, Inc.
 Apogee Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops therapies for immunological and inflammatory disorders | Health Technology |
